Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177082 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
A Phase 1 study, sponsored by Cornea Associates of Texas.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT04177082 is a Phase 1 study that has completed, run by Cornea Associates of Texas. The registered enrollment target is 200 participants.
The verdict
NCT04177082, a Phase 1 study, has completed, sponsored by Cornea Associates of Texas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
Interventions
- COMBINATION_PRODUCT PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177082
The ClinicalTrials.gov registry entry for NCT04177082 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cornea Associates of Texas, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PXL-330 Platinum device for crosslinking with Peschke riboflavin solution is the first listed.
NCT04177082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177082 about?
NCT04177082 is a clinical study titled "Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution". Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
What is the current status of trial NCT04177082?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2020-01-10. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT04177082?
The interventions under investigation include: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04177082?
This trial is sponsored by Cornea Associates of Texas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.